Too much of a risk for Alzheimers Drug

Discussion in 'BiogenIdec' started by anonymous, Feb 28, 2020 at 5:09 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Clones, drones, fakers and ass kissers only need apply
     

  2. anonymous

    anonymous Guest

    It’s amazing that people are still wasting time talking about this. The drug will never be approved. Never.
     
  3. anonymous

    anonymous Guest

    Who are you the self proclaimed anonymous thread monitor? Lmao
     
  4. anonymous

    anonymous Guest

    I think the lame newly hired big pharma clone managers will wind up being the worst part of it all.
     
  5. anonymous

    anonymous Guest

    Wait primary care and specialty targets? Sorry, but once you go specialty you don't go back. I knew those small territories were a red flag...These "counter parts" are they the specialty people and we're the goofers?
     
  6. anonymous

    anonymous Guest

    This is what I was afraid of. However, $200k to d*ck around in pc offices all day isn't the worst way to make a living.
     
  7. anonymous

    anonymous Guest

    200k is a bit of a pipe dream for the territory pod rep positions. Maybe more accurate for reimbursement rep positions. Like others have mentioned, unless you are high risk lay off or out of a job, this position is very iffy. For starters no guarantee of a product anytime soon, mostly big pharma clone DMs, being in a pod with PCP targets....... do your homework. Looks to be desperate escape job that will blow up within 1st 6 months.
     
  8. anonymous

    anonymous Guest

    If you talk to Biogen koolaid drinkers approval is a "slam dunk". Of course that's what everyone who works there is hoping for. And the world needs a new drug for this devastating disease IF it works. And in this case it's a BIG IF. 7 out of 10 analysts give it a very slim chance of approval w/o more data/studies which will take time. And during that time those who joined or transferred from a different division within the company will be out of a job. So as the poster above says doing your homework is critical.
     
  9. anonymous

    anonymous Guest

    This division is going to end up just like Intercept. Always such a risk to accept prior to a drug approval. Good luck.
     
  10. anonymous

    anonymous Guest

    l know folks who went there. And for their sake and more importantly the sake of patients suffering I hope the drug is approved. But hope won’t get it done and unfortunately the data is not strong
     
  11. anonymous

    anonymous Guest

    Data is very weak. Most experts feel, at best, more studies will be needed. More studies would mean at least a couple years of longer delay, and Biogen will simply cut bait with all the new hires. Even if by some miracle the drug is approved, how much can you charge for such modest results?
     
  12. anonymous

    anonymous Guest

    Getting patients to commit to so many treatments at an infusion center for such little benefits at a large cost will be challenging to say the least.
     
  13. anonymous

    anonymous Guest

    It’s all a ginormous shit storm waiting to happen. Everything being mentioned on here. Just don’t see any real advantages to take such a huge leap of faith.
     
  14. anonymous

    anonymous Guest

    Just saw the opening for “Cambridge” and thought, isn’t this a home office backyard territory? I last applied to Biogen in 1998 for Avonex and turned down the hiring manager who was a dick. What’s it like there now?
     
  15. anonymous

    anonymous Guest

    Haha the 90s would have been golden times compared to this dumpster fire now.
     
  16. anonymous

    anonymous Guest

    Maybe good move for the PCP rep wanting to bridge into specialty sales.
     
  17. anonymous

    anonymous Guest

    Worse-much worse. Avonex would have been a dream product versus this drug
     
  18. anonymous

    anonymous Guest

    This will be doing a deal with the devil.
     
  19. anonymous

    anonymous Guest

    How so? I have a good-not-great situation at my current gig, but I am considering applying for this position.

    I don't see any downside should the FDA approve the med.

    Sure, it's expensive & the data isn't ideal but the fact of the matter is that there aren't many options for AD patients.
     
  20. anonymous

    anonymous Guest

    Why would you leave your current job if it’s specialty and stable to come here? Have you not read thru these Biogen threads? This will be typical big pharma shit show on wheels. Cloned big pharma DMs, PITA counterparts, Micro managed metrics, primary care call points........ if these things get you excited, go for it! LMAO